Dr Michael Algus, MD in Bennington, VT - Medicare Pulmonary Disease

Dr Michael Algus, MD is a medicare enrolled "Internal Medicine - Pulmonary Disease" physician in Bennington, Vermont. He went to State University Of New York Downstate Medical Center and graduated in 1979 and has 45 years of diverse experience with area of expertise as Pulmonary Disease. He is a member of the group practice Southwestern Vermont Medical Center Inc and his current practice location is 140 Hospital Dr, Bennington, Vermont. You can reach out to his office (for appointments etc.) via phone at (802) 442-4855.

Dr Michael Algus is licensed to practice in Vermont (license number 0420008429) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1447296223.

Contact Information

	Dr Michael Algus, MD
	140 Hospital Dr, Bennington, VT 05201-5009
	(802) 442-4855
	(802) 442-8706

Physician's Profile

Full Name	Dr Michael Algus
Gender	Male
Speciality	Pulmonary Disease
Experience	45 Years
Location	140 Hospital Dr, Bennington, Vermont
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Dr Michael Algus attended and graduated from State University Of New York Downstate Medical Center in 1979

NPI Data:

NPI Number: 1447296223
Provider Enumeration Date: 06/21/2006
Last Update Date: 07/09/2007

Medicare PECOS Information:

PECOS PAC ID: 6800803693
Enrollment ID: I20060320000706

Medical Identifiers

Medical identifiers for Dr Michael Algus such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1447296223	NPI	-	NPPES
21116	Other	VT	MVP
10000025	Other	VT	CDPHP
0VNO286	Medicaid	VT
18460	Other	VT	BCBS OF VT

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207RP1001X	Internal Medicine - Pulmonary Disease	0420008429 (Vermont)	Primary

Medical Facilities Affiliation

Facility Name	Location	Facility Type
Southwestern Vermont Medical Center	Bennington, VT	Hospital

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
Southwestern Vermont Medical Center Inc	0143138446	142

News Archive

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Effimune announced today that it had received the authorization from the Belgian regulatory authority, the FAMHP (Federal Agency for Medicines and Health Products) for a Phase I clinical trial of FR104, its drug candidate for controlling the regulation of the immune system...

Infants with flat head syndrome may be at increased risk of developmental delays, study finds

Babies with flat head syndrome may be at heightened risk of developmental delays, a new study has found.

How do common mutations in SARS-CoV-2's spike affect its binding affinity with host cell receptors?

Antibodies produced during a previous case of COVID-19 or vaccine-induced immunity are targeted towards S protein, where the neutralizing antibodies attach to the Spike RBD domain. Some of the variants have mutations in their RBD domain, causing resistance to the neutralizing antibodies. However, the effect of these mutations on the affinity and kinetics of the binding of Spike RBD to ACE2 is not clear. A new study has been published on the bioRxiv* preprint server, which deals with the study of affinity and kinetic analysis of the interface between Spike RBD and ACE2 at physiological temperatures.

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Heptares Therapeutics Ltd, the drug discovery company focused on G-protein-coupled receptor (GPCR) targets, announced today that it has entered into an option agreement with the Novartis Option Fund under which Heptares will apply its proprietary StaR(TM) technology to generate novel drug leads against a nominated, unspecified GPCR target of interest to Novartis.

Whole grains in diet translate to multiple health benefits: says research

Whole grains in diet can protect an individual from heart diseases say the CSIRO Food Futures National Research Flagship scientists. According to Dr David Topping, the chef research scientist at CSIRO consumption of whole grains in cereal and breads can reduce the risk of several diseases like obesity, diabetes, high blood pressure, some cancers. Legumes and grains could also prevent asthma, gum disease etc.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Dr Michael Algus allows following entities to bill medicare on his behalf.

Entity Name	Southwestern Vermont Medical Center Inc
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1205865789 PECOS PAC ID: 0143138446 Enrollment ID: O20060929000045

News Archive

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Infants with flat head syndrome may be at increased risk of developmental delays, study finds

Babies with flat head syndrome may be at heightened risk of developmental delays, a new study has found.

How do common mutations in SARS-CoV-2's spike affect its binding affinity with host cell receptors?

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Whole grains in diet translate to multiple health benefits: says research

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Infants with flat head syndrome may be at increased risk of developmental delays, study finds

Babies with flat head syndrome may be at heightened risk of developmental delays, a new study has found.

How do common mutations in SARS-CoV-2's spike affect its binding affinity with host cell receptors?

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Whole grains in diet translate to multiple health benefits: says research

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Michael Algus is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Michael Algus, MD 140 Hospital Dr, Bennington, VT 05201-5009 Ph: (802) 442-4855	Dr Michael Algus, MD 140 Hospital Dr, Bennington, VT 05201-5009 Ph: (802) 442-4855

News Archive

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Infants with flat head syndrome may be at increased risk of developmental delays, study finds

Babies with flat head syndrome may be at heightened risk of developmental delays, a new study has found.

How do common mutations in SARS-CoV-2's spike affect its binding affinity with host cell receptors?

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Whole grains in diet translate to multiple health benefits: says research

Internal Medicine Doctors in Bennington, VT

Khola Qamar, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 140 Hospital Dr Ste 307, Bennington, VT 05201 Phone: 802-447-4555 Fax: 802-447-0996
Dr. Patrick J Tangney, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 140 Hospital Dr Ste 307, Bennington, VT 05201 Phone: 802-447-4555 Fax: 802-440-6087
Dr. David M Gorson, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 140 Hospital Dr, Suite 301, Bennington, VT 05201 Phone: 802-442-3022 Fax: 802-442-4874
Mr. Eric Steven Seyferth, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 140 Hospital Dr, Suite 310, Bennington, VT 05201 Phone: 802-442-7855 Fax: 802-442-6638
Ms. Ashley N Maranino, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 140 Hospital Dr, Suite 104, Bennington, VT 05201 Phone: 802-447-1536
Scott W Rogge, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 140 Hospital Drive, Suite 312, Bennington, VT 05201 Phone: 802-442-0800 Fax: 802-442-0212
David M Sischy, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 140 Hospital Dr, Bennington, VT 05201 Phone: 802-447-8650 Fax: 802-447-8653

Dr Michael Algus, MD - Medicare Pulmonary Disease in Bennington, VT

Contact Information

Physician's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Medical Facilities Affiliation

Group Practice Association

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Infants with flat head syndrome may be at increased risk of developmental delays, study finds

How do common mutations in SARS-CoV-2's spike affect its binding affinity with host cell receptors?

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Whole grains in diet translate to multiple health benefits: says research

Medicare Reassignments

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Infants with flat head syndrome may be at increased risk of developmental delays, study finds

How do common mutations in SARS-CoV-2's spike affect its binding affinity with host cell receptors?

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Whole grains in diet translate to multiple health benefits: says research

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Infants with flat head syndrome may be at increased risk of developmental delays, study finds

How do common mutations in SARS-CoV-2's spike affect its binding affinity with host cell receptors?

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Whole grains in diet translate to multiple health benefits: says research

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Infants with flat head syndrome may be at increased risk of developmental delays, study finds

How do common mutations in SARS-CoV-2's spike affect its binding affinity with host cell receptors?

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Whole grains in diet translate to multiple health benefits: says research

Internal Medicine Doctors in Bennington, VT